Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Ms. Erin E. Lanciani

Chief People & Experience Officer

Mr. Christopher  Benecchi

Chief Business Officer

Dr. Amy  Schacterle Ph.D.

Senior Vice President of R&D Strategy and Business Management

Mr. Mike  Quirk Ph.D.

Chief Scientific Officer

Dr. Laura  Gault M.D., Ph.D.

Chief Medical Officer

Ashley  Kaplowitz

Director of Investor Relations

Mr. Matt  Lasmanis

Chief Technology & Innovation Officer

Ms. Anne Marie Cook Esq.

Senior Vice President, General Counsel & Secretary

Mr. Barry E. Greene

President, Chief Executive Officer & Director

Ms. Kimi E. Iguchi CPA

Chief Financial Officer & Treasurer

Biotechnologie

Sage Therapeutics, Inc.

Sage Therapeutics, Inc. Struktura vedení

Informace o vedení